Filing Flows › Procept BioRobotics (PRCT) › Q3 2026 › vs Q3 2025
Procept BioRobotics (PRCT) Q3 2026 vs Q3 2025 (year over year)
Procept BioRobotics's revenue rose $15.0M (+18%) from $83.3M in Q3 2025 to $98.3M in Q3 2026.
Procept BioRobotics, Q3 2026: revenue $98.3M (+18% year over year), operating margin -27.9%, net loss $26.5M, operating cash flow −$9.0M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $98.3M | $83.3M | $15.0M | +18% |
| Other income, net | $802K | $1.8M | −$1.0M | -56% |
| Income tax benefit | $58K | −$34K | $92K | — |
| Net loss | $26.5M | $21.4M | $5.1M | +24% |
| Costs & expenses | $126M | $107M | $19.1M | +18% |
| Operating costs | $126M | $107M | $19.1M | +18% |
| Cost of revenue | $33.1M | $29.3M | $3.8M | +13% |
| Research & development | $20.0M | $18.2M | $1.8M | +10% |
| SG&A | $72.5M | $59.0M | $13.5M | +23% |
| Operating cash sources | $26.6M | $22.7M | $3.9M | +17% |
| Depreciation & amortization | $2.5M | $1.6M | $922K | +57% |
| Share-based compensation | $15.1M | $14.5M | $590K | +4% |
| Cash used in operations | $9.0M | $6.6M | $2.4M | +35% |
| Net loss absorbed | $26.5M | $21.4M | $5.1M | +24% |
| Working capital & other | $89K | $1.3M | −$1.2M | -93% |
Questions
How much did Procept BioRobotics's revenue grow year over year in Q3 2026?
Procept BioRobotics's revenue rose $15.0M (+18%) from $83.3M in Q3 2025 to $98.3M in Q3 2026.